Premium
Pediatric histiocytic sarcoma clonally related to precursor B‐cell acute lymphoblastic leukemia with homozygous deletion of CDKN2A encoding p16 INK4A
Author(s) -
Kumar Riten,
Khan Shakila P.,
Joshi DivyaDevi,
Shaw Gene R.,
Ketterling Rhett P.,
Feldman Andrew L.
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22810
Subject(s) - cdkn2a , histiocytic sarcoma , histiocyte , malignancy , cancer research , lineage (genetic) , leukemia , sarcoma , medicine , lymphoblastic leukemia , gene rearrangement , acute lymphocytic leukemia , gene , biology , pathology , immunology , genetics
Histiocytic sarcoma (HS) is a rare malignancy of tissue histiocytes with a dismal prognosis. We report a 4‐year‐old male who developed HS during maintenance chemotherapy for precursor B‐cell acute lymphoblastic leukemia (pre‐B ALL). Both tumors showed identical clonal immunoglobulin and T‐cell receptor gene re‐arrangement patterns, as well as homozygous deletion of the CDKN2A gene encoding p16 INK4A . These data suggest a clonal relationship between the two neoplasms despite their distinct lineages. Since CDKN2A deletion predisposes to development of HS in experimental models, the cytogenetic features of the patient's pre‐B ALL may have predisposed to this change in lineage. Pediatr Blood Cancer 2011;56:307–310. © 2010 Wiley‐Liss, Inc.